Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keshaviah, P.
Right arrow Articles by Thorpe, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keshaviah, P.
Right arrow Articles by Thorpe, K. E.
J Am Soc Nephrol 13:S48-S52, 2002
© 2002 American Society of Nephrology


Renal Replacement Therapy

Survival Comparison between Hemodialysis and Peritoneal Dialysis Based on Matched Doses of Delivered Therapy

Prakash Keshaviah*, Allan J. Collins{dagger}, Jennie Z. Ma{ddagger}, David N. Churchill§ and Kevin E. Thorpe§

*Department of Physiology, Himalayan Institute Hospital Trust, Dehradun, U.P., India; {dagger}Minneapolis Medical Research Foundation and University of Minnesota, Minneapolis, Minnesota; {ddagger}University of Tennessee, Memphis, Tennessee; §St. Joseph’s Hospital, McMaster University, Hamilton, Ontario, Canada.

Correspondence to Dr. Allan Collins, Minneapolis Medical Research Foundation and University of Minnesota, 914 South 8th Street, Suite D206, Minneapolis, MN 55404. Phone: 612-347-5811; Fax: 612-347-5878; E-mail: acollins{at}nephrology.org

Abstract

ABSTRACT. Several studies have recently confirmed that hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) survival is highly associated with delivered therapy Kt/Vurea. A direct comparison of equivalently dosed CAPD and HD has not previously been performed. A total of 968 incident HD patients at the Regional Kidney Disease Program from 1987 to June 1995 were studied, and these results were compared with those of the Canadian-United States prospective trial (CANUSA) consisting of 680 incident CAPD patients from September 1990 to December 31, 1992, with follow-up through December 31, 1993. All patients had quantitation of urea nitrogen for a total delivered dialysis session. On HD, in vivo, 2-pool, pre- and post-blood urea nitrogen kinetic modeling was performed with residual renal function determined every 6 mo. Patients were characterized by age, gender, race, renal diagnosis, and comorbid conditions. A Cox proportional hazards model was used to evaluate the effect of the individual comorbid conditions and the effect of dialysis therapy in the time-dependent method. The mean total Kt/V, both residual renal function and dialytic therapy in the HD patients, was 1.59. The CANUSA-delivered weekly Kt/V was 2.38 at the beginning of the baseline period and 1.99 after 24 mo of follow-up. When the peak concentration hypothesis was used, a Kt/V of 1.59 on HD was equivalent to a weekly CAPD dose of 2.1 to 2.2. A 1-unit increase in Kt/V was associated with 7% lower risk of death on HD and with a similar 8% lower risk of death while on CAPD. Patients with diabetes aged 46 to 60 yr had virtually identical 2-yr survival estimates on HD (83 to 90%), compared with CAPD (83 to 89%), with Kt/V ranges from 0.84 to 1.70 in HD and from 1.6 to 2.2 weekly Kt/V on peritoneal dialysis. Comparisons between HD and CAPD in older patients with diabetes yielded comparable results. Patient survival is highly influenced by delivered dialysis in both HD and peritoneal dialysis. Carefully matching of the therapies with delivered Kt/V demonstrates little differences in the survival outcome of HD and peritoneal dialysis patients, in contrast to some previous reports.




This article has been cited by other articles:


Home page
CLIN APPL THROMB HEMOSTHome page
J. Malyszko, J.S. Malyszko, P. Kozminski, K. Pawlak, and M. Mysliwiec
Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule
Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 338 - 345.
[Abstract] [PDF]


Home page
Nephrol Dial TransplantHome page
G. Viglino, L. Neri, S. Alloatti, G. Cabiddu, R. Cocchi, A. Limido, G. Marinangeli, R. Russo, U. Teatini, and F. P. Schena
Analysis of the factors conditioning the diffusion of peritoneal dialysis in Italy
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3601 - 3605.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. M. Chertow
A 43-Year-Old Woman With Chronic Renal Insufficiency
JAMA, March 10, 2004; 291(10): 1252 - 1259.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP